Back to top
more

Vertex Pharmaceuticals (VRTX)

(Delayed Data from NSDQ)

$463.15 USD

463.15
947,949

+1.39 (0.30%)

Updated Sep 26, 2024 04:00 PM ET

After-Market: $463.00 -0.15 (-0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (84 out of 252)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Arpita Dutt headshot

Biotech Stock Roundup: Clovis Soars on Rubraca Data, Seattle Hit by Study Halt

Key highlights in the biotech sector include positive data on Clovis' (CLVS) PARP inhibitor, Rubraca.

    Zacks.com featured highlights: Etsy, Live Nation Entertainment, Salesforce.com, Vertex Pharmaceuticals and NeoGenomics

    Zacks.com featured highlights: Etsy, Live Nation Entertainment, Salesforce.com, Vertex Pharmaceuticals and NeoGenomics

      5 Toxic Stocks to Discard or Play Short for Profit

      If you can pinpoint the toxic stocks accurately, you may gain by resorting to an investing strategy called short selling.

        Zacks.com featured highlights: Salesforce.com, Vertex Pharmaceuticals, Live Nation Entertainment, Covanta Holding and Etsy

        Zacks.com featured highlights: Salesforce.com, Vertex Pharmaceuticals, Live Nation Entertainment, Covanta Holding and Etsy

          5 Toxic Stocks to Offload or Play Short for Profit

          Just like identifying stocks with growth potential, spotting toxic stocks and abandoning them at the right time is the key to protect your portfolio from big losses or make profits by short selling them.

            Why Is Vertex (VRTX) Up 2.1% Since the Last Earnings Report?

            Vertex (VRTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

              Arpita Dutt headshot

              Biotech Stock Roundup: FDA Nod for Regeneron RA Drug, Amgen Hit by Study Data

              Key highlights in the biotech sector include FDA approval for Regeneron's (REGN) Kevzara and data from Amgen and Celgene.

                Concert Pharma Falls After Clinical Hold on Hair Loss Drug

                Concert Pharmaceuticals, Inc. (CNCE) shares were down almost 8% on Wednesday after the company announced that the FDA has placed a clinical hold on a mid-stage study evaluating its pipeline candidate CTP-543 for the treatment of alopecia areata.

                  Vertex Ups Kalydeco Sales View as FDA Okays Label Expansion

                  Vertex Pharmaceuticals Incorporated???s (VRTX) announced that the FDA has approved its lead marketed drug, Kalydeco (ivacaftor) for expanded use.

                    Zacks.com featured highlights: Covanta Holding, PTC, Etsy, Vertex Pharmaceuticals and Live Nation Entertainment

                    Zacks.com featured highlights: Covanta Holding, PTC, Etsy, Vertex Pharmaceuticals and Live Nation Entertainment

                      5 Toxic Stocks to Steer Clear Of or Play Short Right Now

                      High price of the toxic stocks can be ascribed to an irrational exuberance associated with them or some serious fundamental lacunae. Presence of such stocks in your portfolio may result loss of wealth.

                        Arpita Dutt headshot

                        Biotech Stock Roundup: Biogen Inks Deal to Boost Pipeline, Sangamo Soars on Pfizer Deal

                        Quite a few deals were announced this week including by companies like Biogen (BIIB).

                          Why Is Vertex Pharma (VRTX) Stock Soaring This Year?

                          Vertex Pharmaceuticals, Inc.'s (VRTX) shares have risen 57.8% this year so far, outperforming the increase of 1.3% for the Zacks classified Large-Cap Pharma industry.

                            Vertex (VRTX) Q1 Earnings Top, CF Products Sales Strong

                            Vertex Pharmaceuticals Incorporated (VRTX) reported first-quarter 2017 earnings per share of 13 cents (including the impact of stock-based compensation expense), which beat the Zacks Consensus Estimate of 4 cents.

                              What's in Store for Nivalis (NVLS) this Earnings Season?

                              Nivalis Therapeutics, Inc. (NVLS) is expected to report first-quarter 2017 results early next month. Last quarter, the company had a positive surprise of 9.09%.

                                Arpita Dutt headshot

                                Biotech Stock Roundup: Biogen Gains on Strong Q1, NASH Data on Gilead Drug

                                Focus this week remained on Biogen's (BIIB) first quarter results which surpassed expectations.

                                  What's in Store for Vertex (VRTX) this Earnings Season?

                                  Vertex Pharmaceuticals, Inc. (VRTX) is scheduled to report first-quarter 2017 results on Apr 27, after the market closes.

                                    5 Toxic Stocks to Shun or Play Short Right Now

                                    Just like picking up stocks with strong growth potential, pinpointing toxic stocks and abandoning them at the right time is the key to protect your portfolio from big losses or make profits by short selling them.

                                      Mark Vickery headshot

                                      Top Research Reports for Today: MSFT, BLK, NOC

                                      Today's Research Daily features new research reports on 16 major stocks, including Microsoft (MSFT), BlackRock (BLK), and Northrop Grumman (NOC).

                                        TherapeuticsMD Falls on Likely Delay in TX-004HR Approval

                                        Shares of TherapeuticsMD, Inc. (TXMD) have declined almost 25% since Monday when it received a letter from the FDA identifying deficiencies in the new drug application (NDA) for its dyspareunia drug, TX-400HR filed last July

                                          Arpita Dutt headshot

                                          Biotech Stock Roundup: Geron Gains on Interim Data, OncoMed Slumps on Pipeline Setback

                                          Key highlights this week included pipeline updates from companies like Geron (GERN) and OncoMed.

                                            The Zacks Analyst Blog Highlights: Esperion Therapeutics, Vertex Pharmaceuticals, Nektar Therapeutics, Argos Therapeutics and Cidara Therapeutics

                                            The Zacks Analyst Blog Highlights: Esperion Therapeutics, Vertex Pharmaceuticals, Nektar Therapeutics, Argos Therapeutics and Cidara Therapeutics

                                              Vertex Pharmaceuticals (VRTX) Shares March Higher, Can It Continue?

                                              As of late, it has definitely been a great time to be an investor in Vertex Pharmaceuticals Incorporated (VRTX).

                                                Arpita Dutt headshot

                                                3 of the Best & Worst Performing Drug Stocks of Q1

                                                Here is a look at 3 of the best and worst-performing drug stocks in the first quarter of 2017.

                                                  Amgen Files for Xgeva Label Expansion, To Include Myeloma

                                                  Amgen, Inc. (AMGN) recently announced that it has submitted a supplemental Biologics License Application (sBLA) to the FDA to expand the label of its key drug, Xgeva.